Study of Absorbable Biosynthetic Meshes in Contaminated Ventral Hernia Repair

Last updated: November 29, 2021
Sponsor: University Hospital, Strasbourg, France
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hernia

Treatment

N/A

Clinical Study ID

NCT04132986
7398
  • Ages > 18
  • Female

Study Summary

The potential value of biological and biosynthetic meshes is their ability to integrate and remodel the wall in a contaminated environment in complex surgical situations. However, postoperative morbidity and recurrence rate for biologic prostheses are high. The delay to evaluate biosynthetic prostheses is not enough at present, and the high cost of biological prostheses requires a parsimonious use of this type of material. The interest of absorbable biosynthetic prostheses remains to be demonstrated in terms of postoperative complications and long-term recurrence. Current studies have been done on groups with few subjects and in clean surgery.

The primary purpose is to describe the number of complications of the operative site at 12 months, including infectious and noninfectious complications as hematoma and seroma type. The secondary purpose is to describe the number of recurrent ventral hernia at 12 months.

The ventral hernia repair is a frequent operation of general surgery. Thanks to this descriptive work considering the new therapeutic offer with absorbable polymers, it would make possible to update the knowledge of the surgeons and to bring new elements of discussion in the surgical decision.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female adult patient ( ≥18 years)
  • Patient who has agreed to the use of his medical data for the purposes of thisresearch,
  • Patient having been operated between May 2016 and September 2018 in a programmed orurgent surgery, as part of clean / contaminated to dirty surgery at mVHWG grade 3 inthe centers participating in the study,
  • Patient who benefited between May 2016 and September 2018 from a biosynthetic mesh

Exclusion

Exclusion Criteria:

  • Patient who has not consented to the use of her medical data for the purposes of thisresearch,
  • Patients who have benefited from the placement of a Phasix® ST biosynthetic mesh inintraperitoneal or Phasix® in retro-muscular prophylaxis,
  • Patient under safeguard of justice,
  • Patient under guardianship or curatorship.

Study Design

Total Participants: 200
Study Start date:
April 01, 2019
Estimated Completion Date:
June 30, 2023

Connect with a study center

  • Service de chirurgie générale et digestive

    Strasbourg, 67098
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.